Ursane-type triterpenoids, such as ursolic acid and related compounds, have been identified in several medicinal plants and are studied for their diverse biological activities, including potential roles in supporting prostate health. Scientific interest in these compounds for prostate support is largely based on in vitro and in vivo studies that suggest anti-inflammatory, anti-proliferative, and anti-androgenic effects. Several preclinical studies have shown that ursolic acid can inhibit the growth of prostate cancer cells and may reduce inflammation in prostatic tissue, which is relevant to conditions like benign prostatic hyperplasia (BPH) and prostatitis.

For example, studies published in peer-reviewed journals have demonstrated that ursolic acid can induce apoptosis (programmed cell death) in prostate cancer cell lines, reduce expression of androgen receptors, and modulate signaling pathways involved in cell proliferation and inflammation. However, the majority of these findings are limited to laboratory and animal models. There is a lack of robust, large-scale human clinical trials directly evaluating the effects of ursane-type triterpenoids on prostate health or disease outcomes in men.

In summary, while there is promising preclinical evidence suggesting that ursane-type triterpenoids may support prostate health, especially through anti-inflammatory and anti-cancer mechanisms, clinical validation in humans is still limited. Therefore, the evidence level is moderate (3/5), and more research is needed to confirm efficacy and safety in the context of prostate health support.